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ercutaneous Left Atrial Appendage
cclusion for Patients in Atrial Fibrillation
uboptimal for Warfarin Therapy
-Year Results of the PLAATO (Percutaneous Left Atrial
ppendage Transcatheter Occlusion) Study
eter C. Block, MD,* Steven Burstein, MD,† Paul N. Casale, MD,‡ Paul H. Kramer, MD,§
aul Teirstein, MD, David O. Williams, MD,¶ Mark Reisman, MD#
tlanta, Georgia; Los Angeles and San Diego, California; Lancaster, Pennsylvania;
hawnee, Kansas; Providence, Rhode Island; and Seattle, Washington
bjectives The aim of this study was to determine 5-year clinical status for patients treated
ith percutaneous left atrial appendage transcatheter occlusion with the PLAATO (Percutaneous
eft Atrial Appendage Transcatheter Occlusion) system.
ackground Anticoagulation reduces thromboembolism among patients with nonvalvular atrial
brillation (AF). However, warfarin is a challenging medication due to risks of inadequate anti-
oagulation and bleeding. Thus, PLAATO was evaluated as a treatment strategy for nonwarfarin
andidate patients with AF at high risk for stroke.
ethods Sixty-four patients with permanent or paroxysmal AF participated in this observa-
ional, multicenter prospective study. Primary end points were: new major or minor stroke, car-
iac or neurological death, myocardial infarction, or requirement for cardiovascular surgery re-
ated to the procedure within 1 month of the index procedure. Patients were followed for up to
years.
esults Thirty-day freedom from major adverse events rate was 98.4% (95% conﬁdence interval:
0.89% to 99.99%). One patient, who did not receive a PLAATO implant, experienced 2 events
ithin 30 days (cardiovascular surgery, death). Treatment success was 100% 1 month after de-
ice implantation. At 5-year follow-up, there were 7 deaths, 5 major strokes, 3 minor strokes,
cardiac tamponade requiring surgery, 1 probable cerebral hemorrhage/death, and 1 myocardial
nfarction. Only 1 event (cardiac tamponade) was adjudicated as related to the implant proce-
ure. After up to 5 years of follow-up, the annualized stroke/transient ischemic attack (TIA) rate
as 3.8%. The anticipated stroke/TIA rate (with the CHADS2 scoring method) was 6.6%/year.
onclusions The PLAATO system is safe and effective. At 5-year follow-up the annualized stroke/TIA
ate in our patients was 3.8%/year, less than predicted by the CHADS2 scoring system. (J Am Coll
ardiol Intv 2009;2:594–600) © 2009 by the American College of Cardiology Foundation
rom *Emory University, Atlanta, Georgia; †Los Angeles Cardiology Associates, Los Angeles, California; ‡The Heart Group,
ancaster, Pennsylvania; §Shawnee Mission Medical Center, Shawnee, Kansas; Scripps Memorial Hospital, San Diego,
alifornia; ¶The Rhode Island Hospital, Providence, Rhode Island; and the #Swedish Medical Center, Seattle, Washington. This
esearch was supported by ev3, Inc., Plymouth, Minnesota.anuscript received March 16, 2009; revised manuscript received May 4, 2009, accepted May 7, 2009.
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595he PLAATO (Percutaneous Left Atrial Appendage
ranscatheter Occlusion) feasibility study was a nonran-
omized, prospective, 10-center study in which 64 patients
ith permanent or paroxysmal atrial fibrillation (AF) who
ere at high risk for developing thromboembolic events
nderwent percutaneous left atrial appendage (LAA) trans-
atheter occlusion. Patient enrollment was completed No-
ember 18, 2003. Previous reports have documented early
linical experience from this study and a sister study in
See page 601
urope (1–4). The feasibility study in Europe required
ollow-up for only 1 year and consequently is not included
n this report of long-term outcomes. One small study of 11
atients reported reduction of predicted stroke at 3-year
ollow-up (5). We report the 5-year outcomes of patients
nrolled in this North American study.
ethods
ligible subjects were patients with permanent or paroxys-
al AF who were at high risk for developing thromboem-
olic events or stroke, who were not candidates for long-
erm anticoagulation with warfarin. Candidates had to meet
he following inclusion criteria to be eligible: not a candidate
or warfarin therapy (defined as having a contraindication to
arfarin based on warfarin product label, including history
f severe bleeding on warfarin therapy, excessive risk of fall
r hemorrhage, or the inability to maintain a stable inter-
ational normalized ratio (INR) as defined by an INR 3.5
nd/or 1.5 on 2 or more measurements in the prior 1 year
nless due to a warfarin initiation period), chronic (3
onths) continuous or paroxysmal nonrheumatic AF, able
o undergo transesophageal echocardiography (TEE), can-
idate for emergency cardiac surgery (if required), able to
omplete the study follow-up program and provide in-
ormed consent. All patients had to have a total high-risk
CHADS2 [congestive heart failure, hypertension, age,
iabetes, previous stroke]) (6,7) score of 2 or more or
Table 1. High-Risk Clinical and Echocardiographic Inclusion Criteria
Score
2 A prior history of transient ischemic attack or st
1 Diagnosed with congestive heart failure, with a
Section 15.0) or left ventricular ejection fracti
1 Patient has a history of systolic hypertension 
1 Patient has Type I or Type II diabetes mellitus
1 Patient is 65 yrs of age
1 Patient has a history of coronary artery disease,
High-Risk Echocardio
Patient displays high-risk characteristics on transesophageal echocardiography exam
spontaneous echocardiographic contrast in the left atrial appendage.resence of at least 1 high-risk echocardiographic risk
actor, according to the criteria in Table 1. Specific exclu-
ion criteria are listed in Table 2.
The primary study end point was the occurrence of major
dverse events (MAEs) within 1 month of the index
rocedure. A MAE was defined as new major or minor
troke, cardiac or neurological death, myocardial infarction,
r requirement for cardiovascular surgery related to the
LAATO procedure.
Secondary safety end points were: MAEs during the
ospital stay for the index procedure, and presence of
obile left atrial thrombus or MAEs within 6 months of
he index procedure. Secondary effectiveness end points
ere: device success (successful delivery and deployment of
he PLAATO implant into the LAA or recapture and
etrieval if necessary); procedural success (Device Success
nd no MAEs during the hospital stay of the index
rocedure); implantation success (successful delivery and
eployment of the PLAATO implant into the LAA and
he absence of MAEs within 1
onth of the index procedure);
nd treatment success (implan-
ation success and LAA occlu-
ion by TEE at 1 month).
A Clinical Events Committee
CEC) comprising invasive and
oninvasive cardiologists and
eurologists in clinical practice
djudicated in a blinded fashion
ll complications reported dur-
ng the study. All events were
esignated as related to the de-
ice, implantation procedure, or
tudy requirements; not related
o the device or implantation
rocedure; or the relation was unknown. Adjudicated ad-
erse events were categorized as MAEs, serious adverse
vents (SAEs), or adverse events. The CEC adjudication
as the final determination of an event.
h-Risk Clinical Inclusion Criteria
ore than 2 months before the index procedure
de within the prior 100 days (refer to the New York Heart Association deﬁnition in
0% by cardiac catheterization, radionuclide venogram, or echocardiogram
m Hg
d as previous myocardial infarction or known coronary stenosis 50%
ic Inclusion Criteria
, deﬁned as: left atrial appendage velocity 20 cm/s or moderate or dense
Abbreviations
and Acronyms
AF  atrial fibrillation
INR  international
normalized ratio
LAA  left atrial appendage
MAE  major adverse event
NIHSS  National Institutes
of Health Stroke Scale
SAE  serious adverse event
TEE  transesophageal
echocardiography
TIA  transient ischemic
attackHig
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596A total of 64 patients were enrolled at 9 sites in the U.S.
nd 1 Canadian site. Patient enrollment was completed
ovember 18, 2003. Of the 64 subjects, 61 were implanted
ith the PLAATO system.
rocedure. The PLAATO system, used for percutaneous
AA transcatheter occlusion, has been described previously
1–4). Informed consent, baseline demographic data, and
edical history were collected before treatment. Pre-
valuation TEE was performed within 48 h of the proce-
ure. Before the procedure, all subjects received enteric-
oated aspirin, clopidogrel (in case of intolerance,
iclopidine might have been substituted), and amoxicillin (or
ppropriate substitute). Once transseptal access was ob-
ained, heparin was administered and supplemented as
eeded to maintain an activated clotting time of 250 s
hroughout the procedure. An angiogram of the LAA was
one in the most appropriate 2 views (generally a right
nterior cranial/oblique and an anterior/posterior angula-
ion), and the appropriate occluder was selected after mea-
urement of the LAA orifice diameter. Fluoroscopy, an-
iography, and intra-procedural echocardiography were
sed in the guidance of the delivery and evaluation of the
mplant. Intra-procedural echocardiography could be ac-
Table 2. Exclusion Criteria
Prior intracranial hemorrhage
Prior cardiac surgical procedure for left atrial appendage occlusion
Inability to complete transesophageal echocardiography
Mitral stenosis more than mild or signiﬁcant aortic stenosis by echocardiography
Mitral regurgitation more than moderate
Mitral annular calciﬁcation (moderate or severe by echocardiogram)
Left atrial diameter 6.5 cm
Mobile or planar clot in the left atrium or left atrial appendage
Aortic plaque classiﬁed as complex according to mobility, ulceration,
pedunculation, or thickness 4 mm by transesophageal echocardiography
Signiﬁcant abnormality of the intra-atrial septum (such as aneurysm)
Prosthetic heart valve or inferior vena cava ﬁlter
Active endocarditis, infection, sepsis
History of immunodeﬁciency
Acute myocardial infarction, unstable angina, percutaneous coronary
intervention, or coronary artery bypass grafting within 1 month
Symptomatic atherosclerotic carotid artery disease
Known hypercoagulability
Life expectancy 2 yrs
Requires warfarin for nonatrial ﬁbrillation indication
Recent stroke (2 months)
Abnormal laboratory ﬁndings (creatinine 2.5 mg/dl, platelets 100 k,
hemoglobin 10 g/dl, white blood cell count 5,000)
Contraindication to aspirin or other medications prescribed
Pregnant or lactating women
Left ventricular thrombus or high risk for developing left ventricular thrombus,
such as patients with a large dyskinetic left ventricular segment or aneurysm
Any other medical condition that, in the judgment of the investigators, made the
patient a poor candidate for the procedure (e.g., esophageal varices, inability
to lie ﬂat for the procedure)omplished with TEE or intracardiac echocardiography. Ifntracardiac echocardiography was used, a phased array
ystem with a color Doppler feature was employed. Final
mplant position was confirmed by cineangiography with
ontrast medium injections distal to the deployed device (in
he LAA) and in the left atrium as well as by echocardiog-
aphy. The TEE color Doppler was also used to assess for
ossible leaks around the implant’s edges.
ost-procedure medication and follow-up. It was recom-
ended that all subjects be given clopidogrel 75 mg
nce/day (or, if patient unable to take clopidogrel, then
iclopidine 250 mg twice/day) for a period of 4 to 6 weeks
fter the procedure. Subjects were directed to take enteric-
oated aspirin, 325 mg/day indefinitely after the PLAATO
rocedure.
Follow-up visits were required at 1, 3, and 6 months and
n an annual basis for 5 years after the procedure. Data
ollected during follow-up visits included a 12-lead electro-
ardiogram, administration of the National Institutes of
ealth Stroke Scale (NIHSS), complete blood count, and
hest X-ray. In addition, the first 20 patients enrolled were
o receive a TEE at the 1- and 6-month follow-up visits.
ubjects who did not undergo a TEE had a transthoracic
chocardiogram. Any adverse events were documented, and
nformation regarding hospital stays and diagnostic testing
ere obtained and recorded during the follow-up period.
n echocardiography core laboratory (Rhode Island Hos-
ital, Providence, Rhode Island) independently analyzed all
re- and post-PLAATO procedure TEEs and transthoracic
chocardiograms collected as part of the study. Implant seal
f the LAA was assessed with a 5 grade scale (Table 3) from
EE images obtained immediately after procedure and at
ach follow-up visit. Follow-up compliance was 100% (61 of
1) at the 1-month visit and 98.2% (56 of 57) at the 1-year
isit. The study was terminated while most subjects were in
heir fourth year of follow-up, before the 5-year visit.
ubjects were followed for an average of 3.75 years.
esults
atient enrollment included 39 men (60.9%) and 25 women
39.1%) with an average age of 73 years (range 43 to 90
ears). The majority of study patients had been diagnosed
ith AF for more than 3 years (33 of 64; 51.6%) upon study
nrollment. The most prevalent reasons for being poor
andidates for warfarin were excessive risk of falls, history of
Table 3. Echocardiographic Left Atrial Appendage Seal Grade Scale
Grade Description by Echocardiography Core Lab
1 Severe leak, multiple jets of free ﬂow
2 Moderate leak, 3 mm diameter jet
3 Mild leak, 1–3 mm diameter jet
4 Trace, 1 mm diameter jet5 None
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597evere bleeding on warfarin, and inability to maintain a
table INR. Stroke risk estimates were calculated with the
HADS2 stroke-risk index (6,7). Table 4 provides a dis-
ribution of the CHADS2 categories within the PLAATO
tudy population. Table 5 lists the CHADS2 score distri-
ution within the study population, along with each score’s
ssociated stroke risk.
rimary end point. The primary study end point of no
ccurrence of MAEs within 1 month of the index procedure
as met by 63 of 64 (98.43%) patients. One patient had 2
vents (cardiovascular surgery and death).
econdary end points. Table 6 shows the secondary safety
nd effectiveness end points. No device failures or malfunc-
ions occurred during the study. Eight strokes were reported
n 8 patients throughout the course of the study. Five major
trokes (present after 7 days or increased NIHSS by 4)
ccurred at the following times: 216; 979; 1,004; 1,043; and
,586 days after procedure. Three minor strokes (resolved
ompletely within 7 days or increased NIHSS by 3)
ccurred at the following times: 255, 274, and 689 days after
rocedure.
chocardiography core laboratory results. A grade 3 or
etter score was needed to qualify as an effective seal of the
AA. Fifty-five of the 56 patients (98.2%) with assessable
EE data reached this end point. Follow-up TEE and
hest X-ray assessments revealed stable implant position
ith no evidence of migration, erosion, or encroachment on
urrounding structures and smooth healing on the left
trial-facing surface with no thrombus. Table 7 summarizes
he echocardiographic core laboratory results.
A comparison of seal grades between the procedural and
ollow-up TEE assessments can be made in 23 subjects.
eal grades remained stable or improved in 17 of 23
ubjects. Six of the 23 subjects (26%) had a degradation in
eal grades during follow-up, but no seals were observed to
egrade to more than a grade 3. The subject who did not
ave an effective seal (grade 2) of the LAA at the end of the
mplant procedure had a grade 4 seal at the 1-month
ollow-up assessment.
dverse outcomes by CHADS2 scores and seal grades. The
HADS2 scores and LAA seal grades were evaluated
Table 4. CHADS2 Category Distribution
CHADS2
Category Risk Factors
% PLAATO Patients
(n  64)
C Congestive heart failure or left ventricular
ejection fraction 40%
43.8% (28)
H Hypertension 76.6% (49)
A Age 75 yrs 45.3% (29)
D Diabetes 23.4% (15)
S2 Prior stroke/transient ischemic attack 68.8% (22)
PLAATO Percutaneous Left Atrial Appendage Transcatheter Occlusion.mong subjects with MAEs. The 1 subject who experiencedTIA was also included in this evaluation. The distribution
f CHADS2 within this group was similar to the total
ubject population. A CHADS2 score of 3 was the most
ommon, present in 33% of this group. Ten of the 18
ubjects in this evaluation had follow-up TEEs performed,
nd only 2 of the 10 (20%) had a degradation in seal grade
bserved during follow-up. Only 1 event occurred within 6
onths after the implant procedure. Among the 9 subjects
n this group who experienced a neurological event (stroke
r TIA), 7 have follow-up TEE data and only 1 had a
egradation in seal grade. Table 8 summarizes the outcomes
HADS2 scores and LAA seal grades in this group.
HADS2 outcomes. The mean CHADS2 score in the study
opulation was 2.6, resulting in an expected annual stroke/
IA rate of 6.6%. There are 239.9 patient-years reflected in
he study data. Eight strokes and 1 TIA were reported,
esulting in an annualized stroke/TIA rate of 3.8%, almost
ne-half (58%) of the expected stroke/TIA rate (Fig. 1).
IHSS outcomes. National Institutes of Health Stroke Scale
ssessment scores were reviewed for all patients throughout
heir participation in the study. A majority (57.8%, 37 of 64)
f the patients had no change in NIHSS assessment scores
hroughout the course of the study. Scores in 2 patients
3.1%) decreased 3 from prior visits during the study,
hereas scores in 2 patients (3.1%) increased 3 from prior
isits during the study. Scores in 12 patients (18.8%)
ncreased and decreased3 from any prior visit score during
he study. Eight subjects (12.5%) had scores increase and
ecrease 3 from any prior visit score during the study.
nly 12.5% of the study subjects demonstrated changes in
IHSS scores of 3 or greater throughout the course of the
tudy, indicating that the majority of subjects had no
ignificant changes in mental status during their participa-
ion in this study. All NIHSS scores improved at the 3- and
-year follow-up visits compared with both the baseline and
-month visits. Of the 8 patients who experienced strokes
hroughout the course of the study, 6 (75%) had no change
n NIHSS assessment scores after their strokes. One patient
ad an increase 3 after the stroke. One patient experi-
nced a stroke after the 4-year follow-up assessment, but the
Table 5. Baseline CHADS2 Score Distribution
CHADS2 Score Associated Stroke Risk*
% PLAATO Patients
(n  64)
0 0.8% 0
1 2.2% 23.4% (15)
2 4.5% 31.2% (20)
3 8.6% 18.8% (12)
4 10.9% 17.2% (11)
5 12.3% 9.4% (6)
6 13.7% 0
*See reference (7).PLAATO Percutaneous Left Atrial Appendage Transcatheter Occlusion.
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598tudy was terminated before the subject’s 5-year follow-up
indow (Fig. 2).
dverse events. The CEC adjudicated a total of 18 MAEs
or the study: 7 deaths, 5 major strokes, 3 minor strokes, 1
ardiac tamponade requiring surgery, 1 probable cerebral
emorrhage/death, and 1 myocardial infarction. Only 1
vent (cardiac tamponade) was adjudicated as related to the
mplant procedure. The CEC adjudicated a total of 263
AEs for the study. The most common SAE reported was
congestive heart failure”, which occurred 35 times among
2 patients, frequently in relation to an exacerbation of a
re-existing condition.
ummary of deaths. There were 17 reported deaths through-
ut the course of this study. A death was classified as an MAE
hen the cause of death was either cardiac or neurological. Of
Table 6. PLAATO Secondary End Point Results
Secondary Safety End Points
No MAEs during the hospital stay for the index procedure
Absence of mobile left atrial thrombus or MAEs within 6 (6) months of
the index procedure
Secondary Effectiveness End Points
Device success: successful delivery and deployment of the PLAATO implant
into the LAA or recapture and retrieval (if necessary.)
Procedural success: device success and no MAEs during the hospital stay of
the index procedure
Implantation success: successful delivery and deployment of the PLAATO implant
into the LAA and the absence of MAEs within 1 (1) month of the index
procedure
Treatment success is deﬁned as implantation success and LAA occlusion by
echocardiography at 1 (1) month
*Only the first 20 patients were required by the protocol to have the seal leak assessed at the 1-mo
LAA left atrial appendage; MAEmajor adverse event; PLAATO Percutaneous Left Atrial Ap
Table 7. Echocardiography Core Laboratory Assessment of LAA Occlusion
Grade
Procedure
n %
1 0 0.00
2 1 1.79
3 12 26.79
4 29 51.79
5 11 19.64
Total 56 100.00
Not assessable† 2 3.33
Data missing‡ 2 3.33
Percentages are based on the number of patients with assessable echocardiographic data. *Follow
the study. †The PLAATO (Percutaneous Left Atrial Appendage Transcatheter Occlusion) Study devi
recorded.LAA left atrial appendage.he 17 adjudicated deaths, 8 were categorized as MAEs and 9
s SAEs. All of the deaths were categorized as unrelated to the
evice or procedure and were related to patient comorbidities
e.g., renal failure, congestive heart failure).
iscussion
his study supports the use of the PLAATO system for
ercutaneous LAA transcatheter occlusion. The primary
tudy end point rate (98.43%) demonstrates that use of the
LAATO system provided an acceptably safe means of
ercutaneous LAA transcatheter occlusion in patients with
F who were suboptimal candidates for anticoagulation
ith warfarin. More than 98% of patients had satisfactory
AA sealing by echocardiographic core laboratory assess-
Number of Procedures Meeting the End Point Percentage
64 of 65 procedures.
One patient had 2 procedures; the ﬁrst
procedure was MAE-free. During the second
procedure, the patient experienced 2 MAEs.
98.46%
98.46%
61 of 65 procedures.
Three patients did not receive implants;
1 patient had 2 procedures.
93.85%
93.85%
93.85%
22 of 22* 100%
w-up and therefore were the only patients analyzed for the treatment success end point.
e Transcatheter Occlusion.
1-Month* 6-Month*
n % n %
0 0.00 0 0.00
0 0.00 0 0.00
5 22.73 1 5.88
13 59.09 13 76.47
4 18.18 3 17.65
22 100.00 17 100.00
1 4.35 0 0
0 0.00 1 5.56
sesophageal echocardiography (TEE) exams were only required for the first 20 subjects enrolled in
ot assessable during the TEE exam. ‡LAA occlusion grade was unreadable on the TEE exam or notnth follo-up tran
ce was n
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599ent. This was not a randomized study, but one can
peculate whether LAA occlusion with the PLAATO
evice impacted the incidence of stroke in our patients. On
he basis of the CHADS2 score, our study patients had an
Table 8. CHADS2 Scores and LAA Seal Grades in Patients With MAEs/TIA
Patient
ID
CHADS2
Score
LAA Seal Grade
Procedure 1-Month
115-007 4 NA NA
101-003 1 3 3
113-001 2 4 4
107-012 5 3 NA
101-002 3 5 4
101-005 1 3 5
115-003 3 5 NA
123-002 3 NA NA
109-002 3 4 NA
115-006 4 4 NA
109-001 4 3 3
107-002 3 4 5
107-001 2 4 4
115-015 5 4 NA
110-001 4 5 4
121-002 2 4 4
123-008 3 4 NA
101-007 4 4 5
LAA left atrial appendage; MAEmajor adverse event; TIA transient ischemic attack.
Figure 1. Difference Between the Expected Versus Observed Stroke/TIA
Rates in the PLAATO U.S. Feasibility Study
The purple bar represents the expected stroke/transient ischemic attack
(TIA) rate calculated from the patient population CHADS2 score (6.6%). The
actual observed stroke/TIA rate was 3.8% (depicted by the blue bar).
PLAATO  Percutaneous Left Atrial Appendage Transcatheter Occlusion.xpected annual stroke/TIA risk of 6.6%. With up to 5 years
f follow-up, the actual stroke/TIA rate was 3.8%/year—a
2% reduction.
Days After
Procedure Adjudication Description-Month
NA 27 Probable cerebral hemorrhage, death
4 216 Major stroke
3 255 Minor stroke—probable
NA 274 Minor stroke
4 342 Sudden death
4 354 TIA
NA 370 Death
NA 581 Death
NA 682 Death
NA 689 Minor stroke
4 979 Major stroke
4 1004 Major stroke
4 1043 Major stroke
NA 1174 Death
5 1216 Death
3 1342 Death
NA 1399 Myocardial infarction
NA 1586 Major stroke
Figure 2. Kaplan-Meier Analysis of Time to MAE
The table depicts the number of years after the index procedure, the actual
number of patients at risk at each year end, the number of events, and the
percentage of patients free of major adverse events (MAEs). *12 subjects com-
pleted the 5-year follow-up visit prior to early study termination; †17 subjects
had a total of 18 MAEs. One subject experienced 2 MAE events. Solid line 
product-limit estimate curve; circles  censored objectives. PLAATO  Percu-6taneous Left Atrial Appendage Transcatheter Occlusion.
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600Although the safety and effectiveness of the PLAATO
ystem was demonstrated, there are at present no plans to
ursue a pivotal study of the PLAATO system. However,
he recently completed PROTECT-AF (Embolic Protec-
ion in Patients with Atrial Fibrillation) Trial is such a
ivotal, randomized trial (8). This trial uses the Atritech
Plymouth, Minnesota) “Watchman” device for LAA oc-
lusion. The Watchman device differs in design from the
LAATO device. However, the initial trial findings re-
orted at the American College of Cardiology Annual
eeting in 2009 indicate that LAA occlusion with the
atchman device is not inferior to warfarin therapy and
ight be superior in terms of the incidence of hemorrhagic
troke in follow-up. On the basis of these findings, if Food
nd Drug Administration approval is given, it would lead to
he availability of a transcatheter LAA occlusion device that
ould be used for patients that are suboptimal candidates for
arfarin therapy long-term.
tudy limitations. Because this was a safety and feasibility
tudy, it was not randomized, and the patient numbers were
mall. However, each patient did serve as his/her own
control”, which makes the data more easily interpretable.
onclusions
se of the PLAATO system is safe and effectively occludes
he LAA. Although this was not a randomized study, the
troke/TIA rate was 3.8%/year in a population of patients in
hich the anticipated stroke/TIA rate was 6.6% over a
-year follow-up period—a 42% reduction. Peprint requests and correspondence: Dr. Peter C. Block,
mory University Hospital, 1364 Clifton Road Northeast, Suite
606, Atlanta, Georgia 30322. E-mail: pblock@emory.edu.
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